SELECTA BIOSCIENCES INC License Agreements
9 Contracts & Agreements
- License and Development Agreement, dated January 8, 2023, by and between Selecta Biosciences, Inc. and Audentes Therapeutics, Inc (Filed With SEC on March 7, 2024)
- Patent License Agreement by and between Biogen MA, Inc. and Cartesian Therapeutics, Inc., dated September 8, 2023 (Filed With SEC on March 7, 2024)
- Patent License Agreement, between Cartesian Therapeutics, Inc. and the U.S. Department of Health and Human Services, as represented by the National Cancer Institute of the... (Filed With SEC on March 7, 2024)
- Amendment No. 1 to License and Development Agreement, dated as of October 31, 2023, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ) (Filed With SEC on March 7, 2024)
- License and Development Agreement, dated as of June 11, 2020, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ) (Filed With SEC on August 6, 2020)
- Fifth Amendment to Exclusive Patent License Agreement, dated as of May 15, 2020, by and between the Registrant and the Massachusetts Institute of Technology (Filed With SEC on August 6, 2020)
- Fourth Amendment to Exclusive Patent License Agreement, entered into on December 13, 2019, by and between the Massachusetts Institute of Technology and the Registrant (Filed With SEC on March 12, 2020)
- Feasibility Study and License Agreement by and between Asklepios BioPharmaceutical, Inc. and Selecta Biosciences, Inc. dated August 6, 2019 (Filed With SEC on November 8, 2019)
- AMENDED & RESTATED LICENSE AGREEMENT (Filed With SEC on August 11, 2017)
